CTRI/2019/05/018886尚未招募4 期
A prospective, multicenter, open label, randomized controlled trial to evaluate safety and performance of Paximusâ?¢ (Paclitaxel Eluting Percutaneous Transluminal Angioplasty Balloon Catheter) versus Mozecâ?¢ PTA Balloon Catheter for treatment of blocked or narrowed below the knee arteries. - Paximusâ?¢ RCT - 1
Meril Life Sciences Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1. Male or non-pregnant female >=18 to <=80 years of age.
- •2. Patient or his/her legally acceptable representative (LAR) willing to provide informed consent and comply with the required study procedures and visits.
- •3. Patient agrees not to participate in any other investigational or invasive clinical study for a period of 2 years from the date of index procedure.
- •4. Female patient of childbearing potential who does not plan pregnancy for up to 2 years from the date of index procedure. For a female patient of childbearing potential a pregnancy test must be performed with negative results at screening visit.
- •5. Female patient not breast-feeding at the time of the screening visit and will not be breast-feeding for up to 2 years from the date of index procedure.
- •6. Clinically all patients must be in Rutherford category 2 to 5.
- •7. One identifiable single solitary or a series of multiple adjacent lesions in the blocked or narrowed arteries below the knee due toPeripheral Artery Disease (PAD) defined as >=70% diameter stenosis with length in the range of >=20 mm to <=150 mm.
- •8. If the index lesion is re-stenotic, the prior PTA must have been >30 days prior to treatment in the current study
- •9. Patients planned for PK analysis must agree to undergo PK follow-ups as per protocol.
排除标准
- •1. Patient with known hypersensitivity to contrast media or any study-required medication (antiplatelets, anticoagulants, thrombolytics, etc).
- •2. Patient with known allergies or sensitivity to paclitaxel.
- •3. Patient having gastrointestinal bleeding or coagulopathy.
- •4. Patient having target lesion that the investigator is unable to cross by a guide wire.
- •5. Patient judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper of the delivery system.
- •6. Patient is probable case of stenting for the target lesion during the screening as per adjudication of investigator.
- •7. Patient with severe renal insufficiency (serum creatinine >2.0 mg/dL).
- •8. Untreated ipsilateral iliac artery.
- •9. Acute aneurysm in target the target vessel.
- •10. Patient participating in another device or drug study at the time of consenting process.
- •11. Major surgical procedures (viz. major invasive procedures or endovascular interventions for peripheral artery disease etc. or surgeries that might impact safety of participating patients as per discretion of investigator) within 30 days prior to this study or planned within 2 years after entry into this study.
- •12. Patient with life expectancy less than 2 years.
- •13. Adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon etc) within 30 days prior to this study or planned within 30 days of entry into this study.
- •14. Patient who required bailout stenting.
- •15. Diagnosed with cancer or malignancy
- •16. Any medical condition, which in investigatorâ??s opinion, may interfere with patientâ??s participation in the study
研究者
相似试验
进行中（未招募）
不适用
A phase I/II trial for evaluating both safety and preliminary efficacy of one cycle of Promethera HepaStem® in Urea Cycle Disorders and Crigler-Najjar Syndrome patientsCrigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are six disorders: N-Acetylglutamate synthase deficiency, Carbamoyl phosphate synthetase I deficiency, Ornithine transcarbamylase deficiency, citrullinemia, argininosuccinic aciduria and argininemiaMedDRA version: 17.0Level: LLTClassification code 10021601Term: Inborn error of metabolism NOSSystem Organ Class: 100000004850EUCTR2011-004074-28-GBPromethera Biosciences21
尚未招募
2 期
comparative clinical trial to evaluate safety and efficacy of test drug plus standard of care and standard of care alone in COVID 19 Acute Respiratory Distress Syndrome (ARDS) patients with non-invasive ventilation.CTRI/2021/12/038778Reliance Life Sciences Pvt Ltd
进行中（未招募）
不适用
A prospective, open label, randomized, multicenter, multinational study evaluating the overall efficacy and safety including the effect on renal function of sirolimus (Rapamune?) replacing CNI in a standard care regimen of CNI, mycophenolate mofetil (MMF) and steroids in heart transplant patients - Heart STEUCTR2005-001183-31-BEF. Hoffmann-La Roche Ltd650
进行中（未招募）
不适用
A prospective, open label, randomized, multicenter, multinational study evaluating the overall efficacy and safety including the effect on renal function of sirolimus (Rapamune) replacing CNI in a standard care regimen of CNI, mycophenolate mofetil (MMF) and steroids in heart transplant patients - Heart STHeart TransplantEUCTR2005-001183-31-CZF. Hoffmann-La Roche Ltd650
进行中（未招募）
1 期
A prospective, open label, randomized, multicenter, multinational study evaluating the overall efficacy and safety including the effect on renal function of sirolimus (Rapamune) replacing CNI in a standard care regimen of CNI, mycophenolate mofetil (MMF) and steroids in heart transplant patients - Heart STEUCTR2005-001183-31-GBF. Hoffmann-La Roche Ltd650